Amneal Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AMRX in the last 30 days.
See all $AMRX insider activity →Genentech and Novartis sued Amneal Pharmaceuticals and its subsidiary Kashiv BioSciences for allegedly infringing nine patents related to the allergy drug Xolair. The lawsuit follows Amneal's FDA application for ADL-018, a biosimilar version of Xolair, which treats asthma and chronic rhinosinusitis.
Oppenheimer's Fall 2026 SMID-cap stock picks include four Strong Buy-rated companies: Semtech (SMTC, 4.96), Onto Innovation (ONTO, 4.83), Life Time Group (LTH, 4.72), and Pursuit Attractions (PRSU, 4.61). The remaining nine stocks received Hold ratings, with scores ranging from 3.48 to 2.78. Seeking Alpha's Quant Rating system evaluates stocks on valuation, growth, profitability, and momentum.
UBS reiterated a Buy rating on Amneal Pharmaceuticals (AMRX) with a $25.00 price target, citing growth in its hormone replacement therapy patch franchise. The stock is up 94% over the past year. Amneal reported Q2 earnings of $0.30 per share, beating estimates, and revenue of $796.2 million. Oppenheimer initiated coverage with an Outperform rating and $27.00 target, noting the impact of its Kashiv acquisition.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AMRX (Amneal Pharmaceuticals, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent AMRX coverage spans regulation, financial news and market movers.
The lawsuit introduces legal risk to Amneal's biosimilar launch, likely weighing on its share price.
Neutral rating suggests modest effect.
Analyst upgrades and price target raise suggest upside potential.
Positive impact expected from new product launch.
Expands Amneal's generic pipeline in endocrine/oncology space.
AlphAI scores every news story that mentions AMRX with an AI model for sentiment and relevance, and aggregates insider trades from Amneal Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Genentech and Novartis sued Amneal Pharmaceuticals and its subsidiary Kashiv BioSciences for allegedly infringing nine patents related to the allergy drug Xolair. The lawsuit follows Amneal's FDA application for ADL-018, a biosimilar version of Xolair, which treats asthma and chronic rhinosinusitis.
1 min readOppenheimer's Fall 2026 SMID-cap stock picks include four Strong Buy-rated companies: Semtech (SMTC, 4.96), Onto Innovation (ONTO, 4.83), Life Time Group (LTH, 4.72), and Pursuit Attractions (PRSU, 4.61). The remaining nine stocks received Hold ratings, with scores ranging from 3.48 to 2.78. Seeking Alpha's Quant Rating system evaluates stocks on valuation, growth, profitability, and momentum.
2 min readUBS reiterated a Buy rating on Amneal Pharmaceuticals (AMRX) with a $25.00 price target, citing growth in its hormone replacement therapy patch franchise. The stock is up 94% over the past year. Amneal reported Q2 earnings of $0.30 per share, beating estimates, and revenue of $796.2 million. Oppenheimer initiated coverage with an Outperform rating and $27.00 target, noting the impact of its Kashiv acquisition.
2 min readAmneal Pharmaceuticals (AMRX) received FDA approval for its generic lanreotide injection, launching immediately in the U.S. The drug targets acromegaly, GEP NETs, and carcinoid syndrome, adding to AMRX's complex injectables portfolio. Analysts project revenues of $4.1B and earnings of $404.3M by 2029, with potential upside. Key risks include U.S. pricing pressure and debt management.
2 min readSeveral biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.
3 min readAmneal Pharmaceuticals (AMRX) rose 7% to $21.17 after FDA approval for a generic Lanreotide injection. BlossomHill Therapeutics (BLSM) climbed 6% to $27.99 following positive Phase 1/2 study results. Neogen (NEOG) increased 2% to $13.34 after reporting Q4 revenue of $225M. NeoGenomics (NEO) hit a 52-week high of $20.05 after announcing Medicare and Medicaid coverage for its RaDaR ST test.
2 min readAmneal Pharmaceuticals (AMRX) stock surged 12.5% after the FDA approved its generic lanreotide injection for immediate launch. The product targets a market where the reference drug generated $983M in annual U.S. sales. Amneal's shares have seen limited volatility, with this move being rare. The company's stock is up 62% year-to-date, reaching a new 52-week high at $20.51.
2 min readFDA approved Amneal Pharmaceuticals’ lanreotide injection (120 mg/0.5 mL single-dose prefilled syringe), referencing Ipsen’s Somatuline Depot and carrying Competitive Generic Therapy designation. Amneal says it launched immediately. Somatuline Depot had $983M in US sales (12 months ended July 2026).
3 min readAmneal Pharmaceuticals (AMRX) shares rose 2% after-hours following FDA approval of its lanreotide injection, a generic version of Ipsen's Somatuline Depot. The drug, with $983M in U.S. sales (IQVIA), treats growth hormone disorders and tumors. Amneal plans immediate launch, aiming to leverage the product for growth. AMRX stock is up 48% YTD.
2 min readAmneal Pharmaceuticals (AMRX) received FDA approval and launched its lanreotide injection, a generic version of SOMATULINE® Depot, with U.S. sales of $983M for the 12 months ended July 2026. The product, indicated for acromegaly, GEP-NETs, and carcinoid syndrome, has CGT designation and is expected to drive growth for Amneal's Affordable Medicines business.
2 min read
